Compare · ICCM vs MDLN
ICCM vs MDLN
Side-by-side comparison of IceCure Medical Ltd. (ICCM) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCM and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $52.27B, about 4179.6x ICCM ($12.5M).
- Over the past year, ICCM is down 88.1% and MDLN is down 2.3% - MDLN leads by 85.7 points.
- ICCM has been more active in the news (10 items in the past 4 weeks vs 4 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 2 for ICCM).
PerformanceICCM-82.23%MDLN-2.33%
2025-12-17+0.00%2026-07-17
- Company
- IceCure Medical Ltd.
- Medline Inc.
- Price
- $3.63+0.28%
- $39.80-3.23%
- Market cap
- $12.5M
- $52.27B
- 1M return
- +69.23%
- +7.36%
- 1Y return
- -88.08%
- -2.33%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 10
- 4
- Recent ratings
- 2
- 25
ICCM
IceCure Medical Ltd.
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.
Latest ICCM
- IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
- IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
- SEC Form EFFECT filed by IceCure Medical Ltd.
- SEC Form 6-K filed by IceCure Medical Ltd.
- SEC Form 6-K filed by IceCure Medical Ltd.
- SEC Form F-3 filed by IceCure Medical Ltd.
- SEC Form D filed by IceCure Medical Ltd.
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
- IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)